Pomdoctor Limited (POM) posted FY net revenues of RMB399.9M (US$57.2M), up 16.7%. Gross margin fell to 13.1% from 13.9%. Loss per share narrowed to RMB21.96. The next catalyst is whether margin pressure eases.
Alpha Score of 44 reflects weak overall profile with strong momentum, poor value, moderate quality, poor sentiment.
Pomdoctor Limited (POM) filed its fiscal year 2025 results, showing net revenues of RMB399.9 million (US$57.2 million), a 16.7% increase from RMB342.6 million a year earlier. Gross profit rose 9.6% to RMB52.3 million (US$7.5 million). The gross margin, however, contracted to 13.1% from 13.9% in fiscal 2024. Basic and diluted loss per share narrowed to RMB21.96 (US$3.14) from RMB22.72.
The top-line expansion of 16.7% did not produce an equivalent lift in gross profit. Gross profit increased only 9.6%, signaling that the cost of revenue grew faster than sales. The gross margin fell 80 basis points to 13.1%. For a company operating with a thin margin, that compression directly limits the funds available to cover operating expenses.
The revenue figure of RMB399.9 million (US$57.2 million) represents a meaningful step up from the prior year's RMB342.6 million. The growth rate suggests demand for Pomdoctor's services or products remained intact. The margin decline, however, raises the question of whether the company sacrificed pricing power or faced rising input costs to achieve that growth. Without a detailed cost breakdown, the exact driver is not visible from the headline numbers.
The loss per share of RMB21.96 (US$3.14) improved marginally from RMB22.72 in fiscal 2024. The improvement is small in absolute terms, and the per-share loss remains substantial relative to the company's likely share price. The narrowing loss could indicate that operating expenses were contained, even as gross margin slipped. The press release did not provide a breakdown of selling, general, and administrative costs, so the expense trajectory is unclear.
Key figures from the fiscal year 2025 report:
The loss per share remains the central financial metric for a company that is not yet generating net income. The slight narrowing does not change the fact that Pomdoctor is burning cash on a per-share basis. The US dollar equivalent of US$3.14 per share provides a reference point for U.S.-based investors evaluating the stock's valuation.
Pomdoctor Limited trades on the Nasdaq under the ticker POM. The stock's reaction to these results will likely depend on whether the market focuses on the 16.7% revenue growth or the 13.1% gross margin and deep losses. Small-cap Chinese listings on U.S. exchanges often face additional scrutiny around liquidity and accounting transparency, which can amplify moves on earnings releases.
The company did not issue forward guidance in the press release. The next concrete update will probably be the subsequent quarterly filing or any strategic announcement. For broader context on how similar small-cap names are trading, see AlphaScala's stock market analysis.
The stock now trades on the question of whether 16.7% revenue growth can eventually overcome a 13.1% gross margin and deep per-share losses. Until the company demonstrates a path to narrower losses or margin stabilization, the risk-reward remains skewed by the cash burn implied by the loss per share. The next catalyst is any sign that gross margin has bottomed or that operating leverage is starting to appear.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.